BONESUPPORT Q3: Surprising on US sales and EBIT - Redeye

Redeye increases its fair value range following a closer look at the report. We were positively surprised by higher US CERAMENT G sales (ahead of any meaningful trauma indication contribution) and higher EBIT than we estimated. We make minor changes to our estimates on all time horizons and lower our WACC following a review of BONESUPPORT’s qualities.

Länk till analysen i sin helhet: https://www.redeye.se/research/1046951/bonesupport-q3-surprising-on-us-sales-and-ebit?utm_source=finwire&utm_medium=RSS